The effect of dilazep on circulating platelet aggregation in diabetics
Carleo, R.; Buda, G.R.; Cerciello, A.; Dell'Aversano, R.; Monaco, G.P.; Trovato, C.; Vigilante, M.
Bollettino della Societa Italiana di Biologia Sperimentale 59(12): 1832-1837
1983
ISSN/ISBN: 0037-8771 PMID: 6671042 Document Number: 209158
The aim of the present paper was to evaluate the effect of the 1,4 bis [3-(3,4,5-trimethoxybenzoyl-oxy) propyl] perhydro-1,4 diazepina (dilazep) on reduction of circulating platelet aggregates in 18 patients with type 2 diabetes, 13 female and 5 male, aged 25-65 years. Dilazep was orally given at 100 mg X 3/day for 8 weeks. The platelet activity has valued before and after the treatment trough the evaluation of circulating platelet aggregates with the method of Wu and Hoak. The results confirmed that the dilazep decreased statistically significant after 8 weeks the circulating aggregates.